Piper Sandler analyst Jessica Tassan raised the firm’s price target on Tabula Rasa HealthCare to $6 from $4 and keeps a Neutral rating on the shares. The company reported "solid" Q4 results but its gross margin trends "present a significant and underappreciated headwind," the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on TRHC:
- Tabula Rasa HealthCare sees FY23 revenue $343M-$354M, consensus $337.9M
- Tabula Rasa HealthCare sees Q1 revenue $82M-$84M, consensus $76.27M
- Tabula Rasa HealthCare Reports Fourth Quarter and Full Year 2022 Financial Results
- Tabula Rasa HealthCare reports Q4 revenue $82.7M, consensus $81.39M
- Medication Management Services Leader Cureatr Acquires SinfoníaRx